Lutetium Dotatate radiopharmaceutical therapy (Lutathera) was approved by the United States Food and Drug Administration in 2018 and is used to treat somatostatin receptor positive neuroendocrine tumors. With all new radiopharmaceutical therapies, the radiation exposure to members of the public from the patient who received the therapy must be within regulatory limits and safe. If the patient will expose members of the public to too much radiation, the therapy must be performed on an inpatient basis. This paper shows that the administration of Lutathera can be done on an outpatient basis and provides safety and travel restrictions that should be communicated to the patient prior to leaving. The guidance presented herein serves as a basis for medical institutions looking to use Lutathera to treat patients.

中文翻译：

---

镥镥放射性药物治疗的患者释放和说明。

镥Dotatate放射性药物疗法（Lutathera）于2018年获得美国食品和药物管理局批准，用于治疗生长抑素受体阳性神经内分泌肿瘤。对于所有新的放射性药物疗法，接受治疗的患者对公众的辐射暴露必须在监管限制内且安全。如果患者会使公众暴露在过多的辐射下，则必须在住院治疗中进行治疗。本文表明 Lutathera 的给药可以在门诊进行，并提供安全和旅行限制，应在离开患者之前告知患者。本文提出的指南可作为希望使用 Lutathera 治疗患者的医疗机构的基础。